Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival, Costs with First-Line Pazopanib Studied

Adv Ther; 2017 Nov; Vogelzang, Pal, Ghate, et al

Elderly patients with renal cell carcinoma (RCC) treated with first-line pazopanib survived longer than those who received sunitinib, according to an analysis involving >1,000 individuals. Pazopanib treatment also resulted in lower costs and utilization. Participants with RCC were ≥65 years of age and started first-line treatment with either pazopanib (n=522) or sunitinib (n=522). Investigators looked at overall survival, costs, and utilization. Among the results:

  • The group taking pazopanib survived an average of 18.2 months, vs 14.6 months in the contingent receiving sunitinib.
  • All-cause costs were ~$8,800 and ~$10,400, respectively.
  • Inpatient costs were ~$1,500 and ~$2,500, respectively.
  • Inpatient admissions and lengths of inpatient stay were lower in the pazopanib group.

Vogelzang N, Pal S, Ghate S, et al. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: A retrospective Medicare claims analysis. Adv Ther. 2017;34(11):2452-2465. doi:10.1007/s12325-017-0628-2.

This Week's Must Reads

Does Integrated Delivery Treatment Impact Cost? , J Oncol Pract; ePub 2018 Feb 13; Kaye, Min, et al

Anticancer Agent Dose Rounding Cost Impact Assessed, J Oncol Pract; ePub 2018 Feb 5; Fahrenbruch, et al

Employment in Patients with Early-Stage BC Studied , Cancer; ePub 2018 Feb 13; Ekenga, Pérez, et al

Program’s Impact on CRC Screening in Uninsured , Cancer; ePub 2018 Feb 7; Eberth, Thibault, et al

Charting the Landscape of Oncology Pathway Vendors , J Oncol Pract; ePub 2018 Feb 7; Daly, Zon, et al

Must Reads in Renal Cell Carcinoma

Predicting RCC Outcomes After Surgery , Eur Urol; ePub 2018 Feb 2; Leibovich, et al

Partial vs Radical Nephrectomy Impact on Survival , Eur Urol Focus; ePub 2018 Feb 2; Marchioni, et al

Robotic Partial Nephrectomy for Large Renal Masses , BJU Int; ePub 2018 Jan 22; Delto, Paulucci, et al

Trends Examined in the Reporting of RCC Subtypes, Hum Pathol; ePub 2018 Jan 12; Gansler, et al

VEGFR Therapy’s Role in Reducing RCC Progression , Curr Med Res Opin; ePub 2018 Feb 1; Tannir, et al